You are viewing: Japan Cell Expansion Market analysis
Part of: Cell Expansion Market (Global)

The Japan Cell Expansion Market was valued at $13.3 Million in 2024 and projected to reach to $25.2 Million by 2029, representing a compound annual growth rate of 13.6%. Japan's cell expansion market is poised for sustained growth through 2029, driven by increasing investments in regenerative medicine and cell therapy research.

Japan Cell Expansion Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan Cell Expansion Market Trends and Insights

  • Japan is positioned as a key player in the Asia Pacific region's cell expansion sector, driven by advanced healthcare infrastructure and significant investment in regenerative medicine research.
  • The market in Japan reflects strong demand for cell therapy applications and biomanufacturing capabilities that support the country's leadership in precision medicine. The 13.6% compound annual growth rate (CAGR) through 2029 underscores Japan's commitment to cellular therapeutics innovation.
  • Japan's aging population and healthcare system priorities are accelerating adoption of cell expansion technologies across clinical and research settings.
  • Japan continues to attract both domestic and international biopharmaceutical companies seeking to establish cell manufacturing operations, further solidifying the nation's role in the global cell expansion ecosystem..

Key Market Statistics

  • CAGR (2024-2029) 13.6% CAGR
  • Market Size, 2024 ~USD 13.3 Million
  • Forecast, 2029 ~USD 25.2 Million
  • Country Japan

Japan Cell Expansion Market Overview

Market Valuation Growth :

Japan's cell expansion market is valued at $13.3 million in 2024, with a projected CAGR of 13.6% through 2029, reaching $25.2 million. This growth trajectory positions Japan as a significant contributor to the Asia Pacific cell expansion sector.

Advanced Healthcare Infrastructure :

Japan's world-class healthcare system and cutting-edge medical technology ecosystem provide a robust foundation for cell expansion market development. The country's regulatory framework supports innovation in regenerative medicine and cell therapy applications.

Regenerative Medicine Investment :

Significant government and private sector investment in regenerative medicine research drives market expansion in Japan. The nation's commitment to stem cell research and therapeutic development accelerates adoption of cell expansion technologies.

Cell Therapy Demand :

Growing demand for cell therapy applications across oncology, immunotherapy, and regenerative treatments fuels the need for advanced cell expansion solutions. Japan's aging population increases demand for innovative therapeutic approaches.

Japan Cell Expansion Market Dynamics

  • The country's advanced healthcare infrastructure, coupled with strong government support for biotechnology innovation, creates a favorable environment for market expansion.
  • Japanese pharmaceutical and biotech companies are actively developing cell expansion technologies to meet growing therapeutic demands. The market outlook remains positive as Japan continues to establish itself as a regional leader in cell therapy commercialization.
  • Collaborations between academic institutions, government agencies, and private enterprises will accelerate technology adoption.
  • With a CAGR of 13.6%, Japan's cell expansion market is expected to capture increasing market share within Asia Pacific, supported by regulatory clarity and clinical validation of cell-based therapies..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • SANOFI
    • NOVARTIS
    • Pfizer Inc.

      Key Takeaways

      • Japan's cell expansion market is valued at $13.3 million in 2024 and is forecast to nearly double to $25.2 million by 2029.
      • Japan demonstrates a 13.6% CAGR, reflecting strong regional demand for advanced cell therapy and regenerative medicine solutions.
      • Japan's aging demographics and healthcare priorities are driving accelerated adoption of cell expansion technologies across clinical applications.
      • Japan is emerging as a strategic hub for biopharmaceutical companies establishing cell manufacturing and expansion operations in Asia Pacific.

      Cell Expansion Market Report Scope

      Report Metric Details
      Base Year 2024
      Fastest Growing Segment MEDIA (Type)
      Forecast Period 2024–2029
      Growth Rate CAGR of 13.3% from 2024 to 2029
      Largest Segment CONSUMABLES (Product)
      Market Size Base Year (Billions) ~USD 14.3 (2024)
      Revenue Forecast (Billions) ~USD 26.7 (2029)
      Segments Covered Product, Type, Usage

      Japan Cell Expansion Market Report Segmentation

      3 segment dimensions are covered across the global market.

      By Product

      • Consumables
      • Equipment

      By Type

      • Automated Cell Expansion Systems
      • Bioreactors
      • Cell Expansion Bags
      • Cell Factory Systems/Cell Stacks
      • Chemically Defined Media
      • Classical Media & Salts
      • Flasks
      • Hollow Fiber Bioreactors
      • Media
      • Microcarrier Bioreactors
      • Multiwell Plates
      • Other Bioreactors
      • Other Cell Expansion Equipment
      • Other Consumables
      • Other Media Types
      • Petri Dishes
      • Reagents
      • Roller/Roux Bottles
      • Sera
      • Serum-Free Media
      • Specialty Media
      • Stem Cell Culture Media
      • Suspension-Based Independent Bioreactors
      • Vessels

      By Usage

      • Conventional Bioreactors
      • Single-Use Bioreactors

      JAPAN: CELL EXPANSION MARKET, BY END USER, 2022–2029

      Segment20222023202420252026202720282029CAGR (%)
      HOSPITALS & DIAGNOSTIC LABORATORIES79.688.699.5112.2127.1144163.1186.113.3
      OTHER END USERS53.560.16877.388.3100.8115.1132.414.3
      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES243.2274.3311.8356.3408.7469538.1621.714.8
      RESEARCH & ACADEMIC INSTITUTES102.7113.7126.8142.1160180202.6229.512.6
      TOTAL478.9536.6606.1688784.1893.81018.91169.614.1

      Target Audience

      • Biotech & Pharmaceutical Companies : Companies developing cell expansion technologies and therapies need Japan-specific market data to guide product development, clinical trial planning, and commercialization strategies in this high-growth Asian market.
      • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in Japan's regenerative medicine sector require detailed market sizing, growth forecasts, and competitive analysis to support funding decisions and portfolio strategy.
      • Medical Device Manufacturers : Manufacturers of cell expansion equipment and bioreactors need Japan market intelligence to identify demand drivers, regulatory requirements, and customer segments for technology commercialization.
      • Healthcare Consultants & Advisors : Strategy consultants advising clients on Japan market entry or expansion require country-specific market data, growth projections, and competitive insights to develop credible business cases and recommendations.
      • Academic & Research Institutions : Research organizations and universities in Japan need market data to understand commercialization opportunities, identify funding priorities, and align research initiatives with market demand for cell expansion technologies.

      Key Companies in the Japan Cell Expansion Market

      CompanyHQOwnershipStrongest segments
      PATHEON INCNetherlandsPrivate CompanyDrug product services (finished dosage manufacturing and packaging),Pharmaceutical development services,Drug substance services (API and biologics),
      ALLERGAN PLCIrelandPrivate CompanyUS Specialized Therapeutics (incl. Medical Aesthetics & Eye Care),US General Medicine (GI, CNS, Women’s Health, Anti-infectives),International (All Therapeutic Areas),
      EIKEN CHEMICAL CO., LTD.JapanPublic CompanyFecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and media,Immunological and serological reagents,
      MAXCYTE, INCUnited StatesPublic CompanyExPERT GTx and STx instruments,ExPERT ATx and VLx instruments,Processing assemblies (PAs) and consumables,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing hardware, consumables, services),Life Sciences (instruments, genomics, automation, microscopy),Diagnostics (clinical instruments, consumables, software, services),
      MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, equipment),
      SARTORIUS AGGermanyPublic CompanyBioprocess solutions (bioreactors, cell culture, fluid management, process filtration),Analytical instruments and PAT (BLI, cytometry, live-cell imaging, SPR, data analytics),Lab products and services (filtration, purification, lab water, weighing, pipettes, microbiological testing),
      CORNING INCORPORATEDUnited StatesPublic CompanyOptical Communications (fiber, cable, hardware, connectivity),Display Technologies (LCD and OLED glass substrates),Specialty Materials (mobile device glass, optics, wafers, shielding),
      LONZASwitzerlandPublic CompanyIntegrated Biologics (mammalian and drug product platforms),Advanced Synthesis (small molecules, HPAPIs, ADCs and bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
      TERUMO CORPORATIONJapanPublic CompanyCardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company,
      EPPENDORF SEGermanyPrivate CompanyLiquid handling instruments and automation,Separation, PCR, and cold storage instrumentation,Consumables (tubes, tips, plates, plastics),
      FUJIFILM CORPORATIONJapanPublic CompanyHealthcare (medical systems, CDMO, pharma, regenerative medicine, cosmetics/supplements),Electronics (display, semiconductor, image sensor and functional materials, storage, industrial equipment),Business Innovation (office equipment, document solutions, graphic communications, inkjet),
      BIO-TECHNEUnited StatesPublic CompanyProtein Sciences (reagents and proteomic tools),Diagnostics and Spatial Biology,
      REPLIGEN CORPORATIONUnited StatesPublic CompanyChromatography systems, OPUS columns, resins and ligands,Filtration and perfusion (XCell ATF, TangenX, KrosFlo, TFDF, ProConnex),Process analytics and PAT (PATsmart, SoloVPE, ZipChip, REBEL),
      GETINGE ABSwedenPublic CompanyAcute Care Therapies (ECMO, ventilation, monitoring, ICU infrastructure, drainage),Surgical Workflows (OR tables, lights, anesthesia, OR integration, sterile supply management),Life Science (low-temperature sterilization, biocontainment, terminal sterilization, isolation, bioprocess solutions),
      BDUnited StatesPublic CompanyMedical Essentials (syringes, needles, IV and vascular access, sharps, enteral),Connected Care (infusion systems, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, pharma solutions),
      PERKINELMER INC.United StatesPublic CompanyDiagnostics (prenatal, neonatal, infectious disease, immunodiagnostics),Life science reagents and research tools,Instruments and imaging systems,

      PATHEON INC

      Patheon Inc is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and biotechnology sector.

      ALLERGAN PLC

      Allergan PLC is an Ireland-incorporated private company founded in 1983 with 17,400 employees, operating in the pharmaceutical and specialty healthcare industry.

      EIKEN CHEMICAL CO., LTD.

      Eiken Chemical Co., Ltd. is a Japanese public company founded in 1939 with 696 employees, engaged in chemical and diagnostic product manufacturing.

      MAXCYTE, INC

      MaxCyte, Inc is a United States-based public company founded in 1998 with 91 employees, focused on cell engineering and life sciences technology.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.

      DANAHER CORPORATION

      Danaher Corporation is a United States public company founded in 1969 with 59,000 employees, operating across diversified industrial and life sciences sectors.

      MERCK KGAA

      Merck KGaA is a German public company founded in 1668 with 59,077 employees, operating as a global pharmaceutical, chemical, and life sciences enterprise.

      SARTORIUS AG

      Sartorius AG is a German public company founded in 1870 with 14,242 employees, specializing in laboratory and bioprocess equipment and services.

      CORNING INCORPORATED

      Corning Incorporated is a United States public company founded in 1851 with 67,200 employees, manufacturing specialty glass and advanced materials for multiple industries.

      LONZA

      Lonza is a Swiss public company founded in 1897 with 20,000 employees, providing pharmaceutical and biotechnology manufacturing and life sciences solutions.

      TERUMO CORPORATION

      Terumo Corporation is a Japanese public company founded in 1921 with 30,591 employees, specializing in medical devices and blood management products.

      EPPENDORF SE

      Eppendorf SE is a German private company founded in 1945 with 4,358 employees, manufacturing laboratory equipment and consumables for life sciences research.

      FUJIFILM CORPORATION

      Fujifilm Corporation is a Japanese public company founded in 1934 with 73,526 employees, operating across imaging, healthcare, and materials technology sectors.

      BIO-TECHNE

      Bio-Techne is a United States public company founded in 1976 with 3,100 employees, providing life sciences tools and reagents for research and diagnostics.

      REPLIGEN CORPORATION

      Repligen Corporation is a United States public company founded in 1981 with 2,000 employees, specializing in bioprocess chromatography and filtration technologies.

      GETINGE AB

      Getinge AB is a Swedish public company founded in 1904 with 11,754 employees, manufacturing medical devices and systems for healthcare and life sciences.

      BD

      BD is a United States public company founded in 1897 with 72,000 employees, serving as a global leader in medical technology and diagnostic solutions.

      PERKINELMER INC.

      PerkinElmer Inc. is a United States public company founded in 1937 with 11,000 employees, providing diagnostics, life sciences, and applied services solutions.

      Reasons to Buy this Report

      • Market-Specific Sizing & Forecasts : Access precise valuation data for Japan's cell expansion market with detailed 2024-2029 projections. Understand market size dynamics specific to Japan's healthcare landscape and competitive positioning within Asia Pacific.
      • Growth Driver Analysis : Identify key factors accelerating Japan's 13.6% CAGR, including regenerative medicine investments, regulatory support, and cell therapy demand. Understand how Japan's aging population and advanced infrastructure create unique market opportunities.
      • Competitive Landscape Intelligence : Gain insights into Japan-specific market players, partnerships, and innovation trends. Understand competitive dynamics between domestic biotech firms and international companies entering the Japanese market.
      • Strategic Market Entry Planning : Develop informed go-to-market strategies for Japan with country-specific regulatory, reimbursement, and clinical adoption insights. Identify optimal entry points and partnership opportunities in this high-growth market.
      • Investment & Expansion Decisions : Support capital allocation and R&D investment decisions with Japan-focused market data. Evaluate expansion opportunities in regenerative medicine and cell therapy sectors with quantified market potential.

      Frequently asked questions

      What is the current size of Japan's cell expansion market?

      Japan's cell expansion market was valued at $13.3 million in 2024 and is expected to grow to $25.2 million by 2029.

      What is the projected growth rate for Japan's cell expansion market?

      Japan's cell expansion market is projected to grow at a compound annual growth rate (CAGR) of 13.6% from 2024 to 2029.

      What factors are driving growth in Japan's cell expansion market?

      Key drivers include Japan's aging population, advanced healthcare infrastructure, significant regenerative medicine research investment, and increasing adoption of cell therapy applications.

      Why is Japan important in the Asia Pacific cell expansion market?

      Japan is a strategic hub due to its advanced biomanufacturing capabilities, strong regulatory framework, precision medicine leadership, and attraction of international biopharmaceutical companies.

      What applications are driving demand in Japan's cell expansion market?

      Primary applications include regenerative medicine, cell therapy treatments, clinical research, and biopharmaceutical manufacturing operations across Japan's healthcare system.

      RESEARCH METHODOLOGY

      This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global cell expansion market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

      Secondary Research

      Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell expansion market. The secondary sources used for this study include World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), US Food and Drug Administration (FDA), South African Medical Research Council, International Society for Cell & Gene Therapy (ISCT), International Business Magazine, Nasdaq, Center for Strategic & International Studies (CSIS), American Society of Gene & Cell Therapy, Statista; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

      Primary Research

      Extensive primary research was conducted after acquiring basic knowledge about the global cell expansion market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biopharmaceutical companies, research & academic institutes, hospitals & diagnostic laboratories, CROs, and CMOs, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, Middle East, and Africa. Approximately 60% and 40% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

      The following is a breakdown of the primary respondents:

      Cell Expansion Market Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell expansion market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      Bottom-up Approach

      • The key players in the industry and market have been identified through extensive secondary research
      • The revenues generated from the cell expansion business of leading players have been determined through primary and secondary research
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Cell Expansion Market Size, and Share

      To know about the assumptions considered for the study, Request for Free Sample Report

      Top-down Approach

      After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

      Cell Expansion Market Size, and Share

      Data Triangulation

      After arriving at the market size  from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Cell expansion is a process of increasing the number of cells through cell division. Cell expansion is often used for research and therapeutic applications. Cell expansion is also used for manufacturing of cell based therapies such as tissue engineering, cell & gene therapy, and regenerative medicine.

      Stakeholders

      • Cell Expansion Product Manufacturers, Vendors, and Distributors
      • Academic and Research Institutes
      • Pharmaceutical and Biotechnology Companies
      • Hospitals and Diagnostic Laboratories
      • Venture Capitalists and Investors
      • Private Research Firms
      • Contract Research Organizations (CROs)
      • Contract Development and Manufacturing Organizations (CDMOs)

      Report Objectives

      • To define, describe, and forecast the global cell expansion market based on the product, cell type, application, end user, and region
      • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities and challenges)
      • To strategically analyze micro-markets with respect to individual growth trends, future prospects, and contributions to the overall cell expansion market
      • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
      • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To track and analyze competitive developments such as acquisitions, product launches, expansions, and R&D activities in the cell expansion market.

      Available Customizations

      With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

      Portfolio Assessment

      • Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.

      Company Information

      • Detailed analysis and profiling of additional market players (up to three).

      Geographical Analysis

      • A further breakdown of the Rest of Asia Pacific cell expansion market into countries
      • A further breakdown of the Rest of Europe  cell expansion market into countries
      • A further breakdown of the Rest of Latin American cell expansion market into countries
      • A further breakdown of the Rest of Middle East cell expansion market into countries

      Get the Full Cell Expansion Market Report

      Full forecast, segment splits, and company analysis for all Cell Expansion Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status